Front. Med. Frontiers in Medicine Front. Med. 2296-858X Frontiers Media S.A. 10.3389/fmed.2022.888928 Medicine Correction Corrigendum: Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine–A Study Protocol Chopra Arvind 1 Chavan-Gautam Preeti 2 Tillu Girish 2 Saluja Manjit 1 Borse Swapnil 2 Sarmukaddam Sanjeev 1 Chaudhuri Susmita 3 Rao BCS 4 Yadav Babita 4 Srikanth Narayanam 4 Patwardhan Bhushan 2 * 1Center for Rheumatic Diseases, Pune, India 2Center for Complementary and Integrative Health, Interdisciplinary School of Health Sciences, Savitribai Phule Pune University, Pune, India 3Translational Health Science and Technology Institute (THSTI), Faridabad, India 4Central Council for Research in Ayurvedic Science, New Delhi, India

Edited and reviewed by: Zisis Kozlakidis, International Agency for Research on Cancer (IARC), France

 *Correspondence: Bhushan Patwardhan bpatwardhan@gmail.com

This article was submitted to Infectious Diseases Surveillance, Prevention and Treatment, a section of the journal Frontiers in Medicine

 29 03 2022 2022 9 888928 03 03 2022 09 03 2022 Copyright © 2022 Chopra, Chavan-Gautam, Tillu, Saluja, Borse, Sarmukaddam, Chaudhuri, Rao, Yadav, Srikanth and Patwardhan. 2022 Chopra, Chavan-Gautam, Tillu, Saluja, Borse, Sarmukaddam, Chaudhuri, Rao, Yadav, Srikanth and Patwardhan

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine–A Study Protocol by Chopra, A., Chavan-Gautam, P., Tillu, G., Saluja, M., Borse, S., Sarmukaddam, S., Chaudhuri, S., Rao, B. C. S., Yadav, B., Srikanth, N., and Patwardhan, B. (2022). Front. Med. 9:761655. doi: 10.3389/fmed.2022.761655 COVID-19 immunogenicity Withania somnifera vaccine Ayurveda Ashwagandha immunoadjuvant

In the original article, there was an error in the sentence “One tablet of Ashwagandha or placebo will be administered twice daily (on empty stomach in the morning and after dinner) with water.”

The correction has been made to the Eligibility section, “Trial Intervention” sub section and the corrected sentence appears below:

“One tablet of Ashwagandha or placebo will be administered daily (on empty stomach in the morning) with water.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.